Graft-Versus-Host Disease Excellence Forum

Graft-Versus-Host Disease

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Evaluating Strategies and Approaches to Prevent Graft-Versus-Host Disease

08/22/2023

Featuring Benjamin Watkins, MD

Featuring Benjamin Watkins, MD ...

Benjamin Watkins, MD, discusses optimal options and strategies to employ for the prevention of the development of graft-versus-host disease following allogeneic stem cell transplant.

Benjamin Watkins, MD, discusses...

08/22/2023

Oncology

Quiz

Skin Involvement and Disease Severity Estimates for Patients With Chronic Graft-Versus-Host Disease

08/09/2023

True or False: In a study conducted to identify whether the severity of skin involvement of patients with chronic graft-versus-host-disease (GVHD) is a prognostic marker, researchers found that patients with skin involvement, and particularly...

True or False: In a study...

08/09/2023

Oncology

Videos

Post-Transplantation Cyclophosphamide, Tacrolimus, Mycophenolate and Mofetil vs Standard Prophylaxis for Patients With GVHD

07/10/2023

Featuring Javier Bolaños Meade, MD

Featuring Javier Bolaños Meade, MD ...

Javier Bolaños Meade, MD, presents insights from a phase 3 trial on post-transplantation cyclophosphamide, tacrolimus, mycophenolate and mofetil prophylaxis vs standard prophylaxis for patients with graft-versus-host-disease.

Javier Bolaños Meade, MD,...

07/10/2023

Oncology

Videos

Feasibility of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease

05/30/2023

Betty K. Hamilton, MD, Cleveland Clinic, Cleveland, Ohio, discusses the findings of a pilot trial analyzing patient-reported outcomes for the management of patients with acute graft-versus-host-disease.

Betty K. Hamilton, MD, Cleveland...

05/30/2023

Oncology

Videos

Prognostic Value of Cutaneous Disease Severity Estimates for Chronic Graft-Versus-Host Disease

04/05/2023

Emily Baumrin, MD, shares research on the value of cutaneous disease severity estimates in predicting survival outcomes in patients with chronic GVHD.

Emily Baumrin, MD, shares...

04/05/2023

Oncology

Videos

Novel Allogeneic Stem Cell Transplant Strategies to Mitigate Graft-Versus-Host Disease

01/24/2023

Caspian Oliai, MD, MS, provides insight into novel strategies in reducing GVHD, including orca-t cell therapy and post-transplant cyclophosphamide.

Caspian Oliai, MD, MS, provides...

01/24/2023

Oncology

Videos

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil for GVHD Prophylaxis in Reduced Intensity Conditioning

01/24/2023

Shernan G Holtan, MD, discusses findings from a phase 3 study on GVHD prophylaxis in reduced intensity conditioning, which she presented at the 2022 American Society of Hematology (ASH) Annual Meeting & Exposition in New Orleans, LA.

Shernan G Holtan, MD, discusses...

01/24/2023

Oncology

Videos

Latest FDA Approvals for Patients With Steroid-Refractory Graft-Versus-Host Disease

11/22/2022

Yi-Bin Chen, MD, provides insight into the latest FDA approvals for the treatment of patients with acute and chronic graft-versus-host disease.

Yi-Bin Chen, MD, provides...

11/22/2022

Oncology

Yi-Bin Chen, MD, Massachusetts General Hospital

Videos

Itacitinib vs Placebo Combined With Corticosteroids for GVHD: Findings From the GRAVITAS-301 Trial

07/25/2022

Yi-Bin Chen, MD, discusses results from the phase 3 GRAVITAS-301 trial, which evaluated itacitinib vs placebo, both in combination with corticosteroids, for the initial treatment of patients with acute GVHD.

Yi-Bin Chen, MD, discusses...

07/25/2022

Oncology

Aleksandr Lazaryan, MD, Moffitt Cancer Center

Videos

First-Line Ofatumumab Plus Prednisone Demonstrates Promising Efficacy, Safety for Chronic GVHD

06/21/2022

Aleksandr Lazaryan, MD, PhD, MPH, discusses findings from a phase 2 study which explored the efficacy and safety of ofatumumab and prednisone as initial therapy for patients with chronic GVHD.

Aleksandr Lazaryan, MD, PhD,...

06/21/2022

Oncology

Recent News

News

Tacrolimus and Reduced-Dose Methotrexate Combined With Mycophenolate Mofetil to Prevent Graft-Versus-Host Disease

09/28/2023

Gina Tomaine

Tacrolimus plus a reduced-dose of methotrexate combined with mycophenolate for GVHD prevention demonstrated a more favorable toxicity profile compared with the standard-of-care, according to a phase 3 trial.

Tacrolimus plus a reduced-dose...

09/28/2023

Oncology

Conference Insider

Ibrutinib Plus Prednisone Improves Patient-Reported Outcomes in cGVHD

07/01/2021

Ibrutinib given in combination with prednisone has been shown to improve patient-reported outcomes in patients with cGVHD, according to data presented at the EHA Congress.

Ibrutinib given in combination...

07/01/2021

Oncology

News

ROCK2 Inhibition With Belumosudil Yields Promising Results for cGVHD

05/10/2021

Belumosudil produces high overall response rates and demonstrates quality-of-life improvements in patients with chronic graft-vs-host disease.

Belumosudil produces high...

05/10/2021

Oncology

News

Ruxolitinib Active, Well-Tolerated in Patients With Steroid-Refractory Acute GVHD

06/23/2020

In a phase 2 clinical trial, ruxolitinib was well-tolerated and led to responses in >50% of patients with steroid-refractory acute GVHD.

In a phase 2 clinical trial,...

06/23/2020

Oncology

News

Improved Efficacy Outcomes With Ruxolitinib for GVHD After Allogeneic Transplantation

05/13/2020

Ruxolitinib significantly improved efficacy outcomes over common therapy options for patients with glucocorticoid-refractory acute GVHD after allogeneic stem cell transplantation.

Ruxolitinib significantly...

05/13/2020

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology